Related Experiment Video
Updated: Aug 7, 2026
14:45
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
[I131 in blood samples: management in the laboratory]
J Vialard-Miguel1, J Mazère, S Mora
1Service de médecine nucléaire, CHU de Bordeaux, Hôpital du Haut-Lévêque, Pessac. julie.miguel@chu-bordeaux.fr
Annales De Biologie Clinique
|October 19, 2005
Summary
Blood samples from patients treated with radioactive iodine-131 (131I) are safe. Negligible radioactivity ensures no risk to personnel or interference with lab analyses.
Area of Science:
- Nuclear medicine
- Clinical chemistry
- Radiation safety
Context:
- Patients undergoing radioactive iodine-131 (131I) therapy often require blood sampling post-treatment.
- Assessing the safety of these blood samples is crucial for both patient care and laboratory operations.
Purpose:
- To evaluate the radioactivity levels in blood samples from 131I-treated patients.
- To assess the potential risks to healthcare personnel handling these samples.
- To determine if 131I radioactivity interferes with routine laboratory assays.
Summary:
- Radioactivity in blood samples from 131I-treated patients was measured, including dose rate, surface activity, and total activity.
- Personnel exposure risks were evaluated, and interference with automated and immunoradiometric assays (IRMA) was investigated.
- All radioactivity measurements were below European limits, personnel irradiation was negligible, and no analytical interferences were observed.
Impact:
- Confirms the safety of collecting blood samples from patients treated with 131I.
- Reassures healthcare professionals regarding negligible radiation exposure risks.
- Validates the integrity of laboratory test results despite the presence of low-level 131I radioactivity.
